JSPR
JSPR
NASDAQ · Biotechnology

Jasper Therapeutics Inc

$1.05
-0.06 (-5.41%)
As of Mar 29, 10:51 PM ET ·
Financial Highlights (FY 2025)
Revenue
6.30M
Net Income
-1,316,650
Gross Margin
36.3%
Profit Margin
-20.9%
Rev Growth
-2.8%
D/E Ratio
0.17
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 36.3% 36.3% 36.3%
Operating Margin -26.0% -28.5% -30.1%
Profit Margin -20.9% -24.3% -23.0%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 6.30M 6.48M 4.92M
Gross Profit 2.29M 2.35M 1.79M
Operating Income -1,638,161 -1,847,331 -1,477,660
Net Income -1,316,650 -1,573,823 -1,131,717
Gross Margin 36.3% 36.3% 36.3%
Operating Margin -26.0% -28.5% -30.1%
Profit Margin -20.9% -24.3% -23.0%
Rev Growth -2.8% +6.4% +0.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 5.02M 4.24M 5.06M
Total Equity 28.74M 31.24M 26.47M
D/E Ratio 0.17 0.14 0.19
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -2,363,922 -2,326,744 -1,866,701
Free Cash Flow -1,722,588 -1,580,767 -1,263,847